Algert Global LLC Has $3.03 Million Position in STAAR Surgical (NASDAQ:STAA)

Algert Global LLC lessened its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 30.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,528 shares of the medical instruments supplier's stock after selling 35,127 shares during the quarter. Algert Global LLC owned approximately 0.17% of STAAR Surgical worth $3,029,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in STAA. Geneva Capital Management LLC lifted its holdings in STAAR Surgical by 0.3% during the 3rd quarter. Geneva Capital Management LLC now owns 695,415 shares of the medical instruments supplier's stock worth $25,835,000 after buying an additional 2,241 shares during the period. Defender Capital LLC. boosted its holdings in STAAR Surgical by 4.4% in the third quarter. Defender Capital LLC. now owns 677,617 shares of the medical instruments supplier's stock valued at $25,173,000 after acquiring an additional 28,430 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in STAAR Surgical by 50.1% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier's stock valued at $28,215,000 after acquiring an additional 197,717 shares during the last quarter. Dimensional Fund Advisors LP increased its position in STAAR Surgical by 25.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier's stock valued at $21,884,000 after purchasing an additional 94,422 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in STAAR Surgical by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 405,222 shares of the medical instruments supplier's stock worth $19,293,000 after purchasing an additional 5,712 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on STAA. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, October 31st. Canaccord Genuity Group decreased their price target on STAAR Surgical from $41.00 to $31.00 and set a "hold" rating for the company in a report on Friday, November 1st. Finally, Stifel Nicolaus cut their target price on STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday, August 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $43.33.

STAAR Surgical Stock Performance

Shares of NASDAQ STAA traded up $0.73 during trading on Wednesday, hitting $28.79. 112,182 shares of the company traded hands, compared to its average volume of 707,966. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 65.43 and a beta of 0.61. The business's fifty day moving average is $30.82 and its 200 day moving average is $36.47. STAAR Surgical has a fifty-two week low of $25.88 and a fifty-two week high of $52.68.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.